Heparin induced thrombocytopenia (HIT) is a potentially fatal condition that arises subsequent to formation of antibodies against complexes containing heparin, usually platelet-factor 4-heparin ("anti-PF4-heparin"). Assessment for HIT involves both clinical evaluation and, if indicated, laboratory testing for confirmation or exclusion, typically using an initial immunological assay ("screening"), and only if positive, a secondary functional assay for confirmation. Many different immunological and functional assays have been developed. The most common contemporary immunological assays comprise enzyme-linked immunosorbent assay [ELISA], chemiluminescence, lateral flow, and particle gel techniques. The most common functional assays measure platelet aggregation or platelet activation events (e.g., serotonin release assay; heparin-induced platelet activation (HIPA); flow cytometry). All assays have some sensitivity and specificity to HIT antibodies, but differ in terms of relative sensitivity and specificity for pathological HIT, as well as false negative and false positive error rate. This brief article overviews the different available laboratory methods, as well as providing a suggested approach to diagnosis or exclusion of HIT.
| B AC KGR OUND A ND H I STOR I CA L P E RSP E CTI V E
The anticoagulant heparin is given to patients for many reasons, including anticoagulant therapy to treat or prevent thrombosis, to maintain patency of circuits during operative procedures (e.g., cardiac surgery), and to maintain patency of central lines. 1 Heparin induced thrombocytopenia (HIT) is a potentially fatal condition that arises subsequent to formation of antibodies against complexes containing heparin, usually platelet-factor 4-heparin ("anti-PF4-heparin"). The antibodies lead to binding and clearance of platelets from the circulation (the "thrombocytopenic" event). 2 In pathological HIT, the antibodies lead to platelet activation which in turn leads to thrombosis, with possible organ damage, and potentially fatal outcome if not recognized and treated. 2 Assessment for HIT involves both clinical evaluation and, if indicated, laboratory testing for confirmation or exclusion. 3, 4 Clinical evaluation usually entails a pretest probability assessment for HIT, with the 4T score (4Ts) representing the most commonly used; 4Ts assesses evidence of Thrombocytopenia, the Timing of any platelet fall, the presence of Thrombosis, as well as oTher potential causes of the thrombocytopenia. 4 Other clinical evaluation models are, however, available. 3 Depending on the 4Ts (or other clinical guidance), laboratory testing for HIT antibodies may ensue, typically using an initial immunological ("screening") assay, and only if positive, a secondary functional assay for confirmation. It is important that some form of pretest clinical assessment be undertaken because of the high risk of "false positives" with the screening tests. Inappropriately managing these patients by altering therapy to nonheparin anticoagulants, or withdrawing anticoagulant therapy altogether, carries substantial risk. 3 All aspects of the identification or exclusion of HIT have an interesting historical course. As this article relates to laboratory tests, it will provide a brief historical overview of immunological and functional HIT assays. Notably, much relevant history has already been recently explored in this journal. 5, 6 Immunological assays assess for HIT antibodies using a solid phase and labelled animal antibodies directed against human IgG or IgM; the presence of these labelled antibodies can be measured by different test systems, and the IgG class antibodies are more clinically important. 2, 3 Functional HIT assays assess for platelet activation, which can also be measured in several ways. 3, 5, 6 Interestingly, initial reports around laboratory testing for HIT mostly comprised functional assays performed to assess platelet aggregation in response to patient sera in the presence of heparin. 7, 8 Experience from my own laboratory suggests that using standard light transmission aggregometry (LTA) to assess functional HIT reflects perhaps the least sensitive approach among current technologies. 9 Many different immunological and functional assays have been developed from the first reports. The most common contemporary immunological assays comprise enzyme-linked immunosorbent assay [ELISA], chemiluminescence, lateral flow and particle gel techniques. 3 The most common functional assays still comprise platelet aggregation or platelet activation, but for the former, whole blood aggregation (WBA), for example using the Multiplate system, seems more sensitive to pathological HIT than classical LTA. 9 However, assays that assess platelet activation events, which precedes platelet aggregation, as theoretically measured by release of internalized platelet components (e.g., serotonin release assay; SRA) or exposure of external platelet receptors (typically by flow cytometry), are even more potentially sensitive than aggregation assays. 3, 5, 6 Many other methodologies have now been reported in the research environment. 3 Some functional assays, in particular SRA and HIPA (heparin-induced platelet activation), are considered "gold-standards" for identification of pathological HIT, including as recommended by the ISTH SSC (International Society on Thrombosis and Haemostasis Scientific Standardisation Committee) on HIT.
10,11
Preanalytical and analytical considerations depend on the test employed.
Most immunological assays, attempting to identify antibodies captured onto a solid phase, prefer serum over plasma, although plasma may also be suitable. Under-recognized is that citrate plasma represents a slight dilution (10%) over serum, which may cause antibodies in a plasma sample to be under-read slightly (relative to serum); this is potentially important if the end test result is at the negative/positive cut-off region.
Conversely, it could easily be argued that for most functional assays, plasma should be the preferred sample. This is because generation of serum may in itself generate platelet activation through mechanisms other than HIT antibodies (e.g., thrombin generation, complement), thereby causing false positive results in functional HIT testing. Although this may be overcome by a heat inactivation procedure, this is not fool-proof, and heat inactivation of serum is discouraged by some experts because this may generate antibody aggregates, which may themselves create false positive events. 6 Moreover, heat inactivation is also discouraged for Multiplate testing as it seems to reduce reactivity in this system. 12 All assays have some sensitivity and specificity to HIT antibodies, but assays differ in terms of their relative sensitivity/specificity, as well as their false negative/positive error rate. In general, immunological assays are more sensitive to HIT than functional assays, but functional assays are much more specific for pathological HIT. In our experience, ELISA was found to be more sensitive, for example, than either lateral flow or chemiluminescence, but chemiluminescence yielded fewer "false positives" than ELISA, and thus expressed greater potential specificity for pathological HIT. 9 On the other hand, the ELISA procedure was less prone to missing HIT than either lateral flow or chemiluminescence. 9 Analogously, LTA showed poorer sensitivity and specificity compared to the Multiplate system, but seemed less prone to false positives. 9 However, our laboratory's experience with HIT testing may or may not reflect the experience of other workers in the field; such is the complicated landscape which HIT testing reflects. Importantly, the specificity of functional assays can be increased by adding a second test event, namely exposure of the test system to patient sample and platelets as per normal, but replacing a therapeutic heparin level with a supra-therapeutic level, which acts to swamp any antibodies and give a reduced or absent activation/aggregation event. 3, 6 Because of these considerations, it is typically recommended that high clinical suspicion (e.g., if the 4Ts score reflects intermediate or high probability) for HIT is followed by an immunological assay, which will likely detect HIT antibodies, and then a functional assay only employed where indicated, 3, 6, [10] [11] [12] [13] What tests are employed within a given institution is driven by both personal experience/bias and prior existence/experience of available technologies. Here, the requirement for regulatory approval may actually prevent local availability of some methodologies. As examples, those with an AcuStar instrument will likely and pragmatically employ the chemiluminescence procedure for immunological HIT testing, those with ELISA technology will likely employ this technology, those with appropriate blood-banking equipment may employ particle gel techniques, and those without any such equipment may employ the lateral FIGURE 1 An algorithm that reflects a recommended approach to the investigation of individuals with potential heparin induced thrombocytopenia (HIT), based on local 3,9 and other published experience. Notes: *Strongly recommended that the decision to perform HIT testing in cases with low 4Ts only progress after consultation with a local hematology expert. **Be aware that occasional immunological test results will be falsely negative (albeit probably <5%). Serial reassessment, or assessment with more than one type of immunological assay, may be required for some patients (especially those with strong clinical suspicion for HIT) [Color figure can be viewed at wileyonlinelibrary.com] flow procedure. 14 Similarly, SRA cannot be performed without a radioactive counting system, flow cytometry requires a flow cytometer, and aggregation requires an aggregometer, be it either LTA or whole blood/Multiplate. 3 However, regulatory approval for a given method may also be required in some localities.
Another important consideration is turn-around time. Because of the potentially catastrophic nature of pathological HIT, its identification/exclusion is typically required "immediately." Thus, those tests that provide quick ("rapid") test results are often preferred. Here, tests such as lateral flow, able to be performed in 15 minutes by any operator,
and not needing any instrumentation other than a pipette, seems an ideal choice. 3, 9, 14 However, such quick turn-around may need to be tempered by recognition that some tests may fail to identify occasional pathological HIT, and some test batches may also "over-call" HIT by yielding a high proportion of equivocal or positive tests, of which most will not turn out to be pathological HIT. 9 In a recent study from my laboratory, an ELISA test system showed similar specificity to the lateral flow method 9 ; however, a recently published meta-analysis suggested that the lateral flow method had better specificity than the ELISA test process. 15 There may be several explanations to this potential discrepancy, including relatively poor performance of recent batches of the lateral flow method, as tested by our laboratory, and relatively good performance of the ELISA assay used in our study, compared to previously published literature which may represent a mixture of commercial methods. 15 Other rapid immunological assays are the particle gel system (PaGIA) and the AcuStar; these have also been identified to occasionally miss pathological HIT, and also detect "false" positives (i.e., those that will not turn out to be pathological HIT). Moreover, they require instrumentation and more expertise than the lateral flow procedure. Notably, the recently published meta-analysis suggested that some improvement over time has occurred for the PaGIA system. 15 ELISA testing is also excellent in terms of identifying HIT, but may also over-call HIT, 9,15 and again requires instrumentation; moreover, the test turn-around-time is least favorable among the standard methods.
3,9 Table 1 provides a summary of available laboratory tests for HIT.
| U T IL I TY OR OTHE R WI S E OF H I T T ESTIN G
Most workers in the field agree that laboratory testing for HIT has clinical and management utility. However, the perceived utility may be a matter of debate and relative experience. The perspective from our practice has recently been reported. 3, 9 First, it needs to be recognized that clinical assessment is not fool-proof, and will not be 100% accurate for diagnosis. Importantly, the most commonly used clinical screening tool, the 4Ts, has excellent negative predictive value (NPV), but only moderate positive predictive value (PPV). The 4Ts essentially provides a pretest probability score of the likelihood of HIT, with scores of 0-3, 4-5, and 6-8 respectively identifying low, intermediate and high probability for HIT. In a meta-analysis of 13 studies, the NPV of a low probability 4Ts score was 99.8% (95% CI: 97.0-100.0%), and remained high irrespective of who undertook the score, the composition of the study population, or the prevalence of HIT [4] . The PPV of the 4Ts, however, is low (9-17%), with differential PPV of 14% (95% CI: 9-22%) for an intermediate and 64% (95% CI: 40-82%) for high probability 4Ts score, respectively.
5,11
From a practical perspective, one can translate this background to simply: a low 4Ts usually excludes HIT (however, it does not always), and a high 4Ts does not categorically prove HIT (it is often something else).
Thus, laboratory testing is always required for confirmation of HIT.
Most workers agree that laboratory testing should be undertaken for confirmation of suspected HIT where 4Ts are in the intermediate or high range; most workers also suggest that laboratory testing can be omitted if 4Ts is in the low range. 3 Our own experience with the 4Ts In terms of individual tests, as previously noted, each has differential sensitivity and specificity for HIT. In our experience, sensitivity for HIT is similar for the 3 immunological assays we have recently evaluated (ELISA, AcuStar, lateral flow), but ELISA and lateral flow generated comparatively many false positives than the AcuStar method, meaning HIT is over-called. 9 This may lead to potential inappropriate cessation of heparin therapy and associated risks, 3 as well as unnecessary performance of an increased number of functional assays, thereby increasing costs and delaying HIT diagnosis/exclusion. On the other hand, it is important that immunological assays do not miss HIT (i.e., do not generate false negatives), as this will lead to continued therapy with heparin and potentially catastrophic outcomes. 2, 3 Unfortunately, most immunological assays will generate an occasional false negative. 3, 9 Conversely, the main value of the functional assays is to confirm or exclude pathological HIT, meaning that these need to be highly specific for pathological HIT. The most commonly recognized "gold-standard" functional assays are the SRA and HIPA. 3, 6, 10 To provide some balance here, since there are no clearly superior functional HIT assays, determining the true vs false positive and negative rates for SRA and HIPA would be difficult. Certainly, false positives and negatives would be feasible with any functional procedure, including SRA and HIPA.
| F U TU RE P E RS P E CTI V E
It is interesting that laboratory testing for HIT continues to evolve. Perhaps most interesting is the movement in "functional" assays. Although SRA is perhaps regarded as the ultimate gold standard functional assay for pathogenic HIT, the test is being offered by fewer and fewer laboratories, due to test complexity and use of radioisotopes/specialised equipment. Future assays to potentially supplant SRA include newer HPLC methods, 3, 16 although such procedures are similarly complex and May not be 100% NPV; some HIT antibodies will occasionally be missed
Particle gel immunoassay (Pa-GIA) Commercial method that uses PF4/heparin complexes bound to red, high-density polystyrene beads, which after centrifugation, agglutinate in the presence of anti-PF4/heparin antibodies, and thereby do not migrate through the sephacryl gel (whereas nonagglutinated beads indicate the absence of antibodies and pass through the gel and may form a cell pellet). [17] [18] [19] [20] methods; however, standardization issues, instrumentation requirements and potential for lower sensitivity for pathological HIT compared to SRA may delay their more comprehensive take up.
| C ONC LUSI ON
The proposed diagnostic approach for HIT diagnosis/exclusion would begin with an initial pretest probability assessment (e.g., with 4Ts), but would not necessarily suggest omission of laboratory testing for low probability patients (potentially dependent on the speed and reliability of the laboratory testing vs the need for urgent clinical decisions, as well as the expertise of the clinicians involved) (Figure 1) . For low probability patients, an occasional patient will be "pathological" HIT positive, and for high probability patients, many will not be "pathological" HIT positive. Immunological assays should be used to screen for HIT, ahead of performance of functional assays, for all intermediate and high probability HIT patients by 4Ts, as well as the occasional low probability patient by 4Ts, where expert clinical suspicion remains sufficiently high. Which immunological assay a laboratory will select for HIT "screening" will depend on locally available/ approved technologies, and the relative strengths and weaknesses of each assay, including individual rates of false negatives and positives, as well as test turn-around-time. Similarly, which functional assay a laboratory will select for HIT "confirmation" will also depend on locally available/approved technologies, the relative strengths and weaknesses of these assays, and their turn-around time. In the end, the diagnosis or exclusion of HIT is a sum of the many "imperfect" parts involved.
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Laboratory testing for heparin induced thrombocytopenia (HIT) is a critical component of confirmation or exclusion of the disease. Most tests assess for the presence of antibodies against platelet factor 4/ heparin complex ("anti-PF4-heparin").
How is it measured?
Laboratory tests comprise two main categories -immunological What conditions or types of conditions is it used for?
Laboratory testing for HIT antibodies is utilized for investigation (confirmation or exclusion) of suspected pathological HIT.
What tests are helpful to do with it for a more complete picture?
Performance of laboratory testing for HIT antibodies occurs in consequence to clinical suspicion of pathological HIT. According to the clinical evaluation process, a pretest probability assessment should be undertaken, of which the 4T score is most widely used. This includes assessment of platelet count and recent pattern of changes, as well as assessment of thrombosis.
What tests provide similar information?
All immunological tests for HIT antibodies provide "similar" information, but may vary in terms of their sensitivity or specificity. 
